Medivation lines up cancer drug deal — with an escape By: San Francisco Business Times via Business Journals October 24, 2014 at 16:48 PM EDT Medivation Inc. broadened its cancer drug portfolio in a low-risk deal with a $5 million upfront payment and an escape hatch... Read More >> Related Stocks: Astellas Pharma Inc